Evidence map›Paper›PMID 42495709›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026

Developing an integrated medication event monitoring system and smartphone-based ecological momentary assessment delivery platform to identify real-time factors influencing TB treatment adherence in South Africa.

Tamara Jimah, Jacob A M Stadler, Zizipho Bota, Lloyd A Marshall, Ryan Johnson, Aaron Kipp, Sean Wasserman, Catherine Orrell, Joseph Daniels, Andrew Medina-Marino

Abstract read
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tamara JimahDepartment of Public Health and Health Sciences, Department of Pharmacy and Health Systems Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA.
Jacob A M StadlerCentre for Infectious Diseases Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Zizipho BotaNelson Mandela University, Gqeberha, South Africa.
Lloyd A MarshallWisepill Technologies, Cape Town, South Africa.
Ryan JohnsonCenter for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.
Aaron KippDepartment of Public Health, East Carolina University Brody School of Medicine, Greenville, NC, USA.
Sean WassermanCentre for Global Health, Institute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Catherine OrrellDesmond Tutu HIV Centre, Cape Town, South Africa.
Joseph DanielsEdson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA.
Andrew Medina-MarinoDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Identifying real-time factors influencing adherence to Tuberculosis (TB) treatment is critical for informing treatment support interventions. Studies often use methods prone to recall bias, failing to capture objective real-time adherence-related factors. Objective: To develop and test the functionality of an integrated medication event monitoring system and modified ecological momentary assessment (MEMS-mEMA) technology platform to collect real-time data on factors influencing daily dosing of drug-susceptible TB treatment. Methods: We developed backend technology integrating a medication event monitoring (MEM) device with REDCap to deliver electronic surveys. System functionality was tested among individuals initiating TB treatment who received a Wisepill MEM device to store medication and capture dosing data, using device openings as a proxy for medication intake. Modified EMA (mEMA) surveys were administered randomly once every rolling seven days, and when the MEM device was not opened. In-depth interviews, followed by rapid qualitative analysis, were conducted to capture user experiences. Device openings and the total number of EMA surveys delivered and completed, including response rates, were presented. Results: We successfully developed and tested the MEMS-mEMA system for collecting data on factors influencing TB treatment adherence. Ten adults newly initiating TB treatment participated in a pilot study for two months (male = 7; female = 3); mean age = 37 years (SD ±13.1), 50% living with TB/HIV coinfection. The median number of days the MEM device was opened during the two-month intensive treatment phase was 61 days. Participants demonstrated good comprehension of study requirements and did not report major challenges responding to surveys. Conclusions: Findings suggest that this novel platform can collect real-time data on factors influencing TB treatment adherence for a larger feasibility study to inform intervention development in South Africa.

Indexed as

Digital adherence technologyDrug-susceptible TBEastern Cape, South AfricaEMATB treatment adherence

Identifiers

PMID42495709
PMCPMC13393155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.